Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

LiverChip Platform Tested

By Drug Discovery Trends Editor | December 3, 2013

Zyoxel has announced preliminary results from a testing by Sanofi on Zyoxel’s  LiverChip platform for drug metabolism and pharmacokinetic (DMPK) studies. (Source: Zyoxel)Zyoxel has announced preliminary results from a testing by Sanofi on Zyoxel’s  LiverChip platform for drug metabolism and pharmacokinetic (DMPK) studies. Sanofi employed a variety of morphological, genetic and functional analyses to fully characterise the LiverChip system, the full findings of which will be presented as part of Zyoxel’s In Vitro Liver Technology Symposium taking place on Dec. 10, 2013 in Oxford, UK.
 
Under the terms of an Equipment Hire Agreement, Sanofi has been exploring the utility of Zyoxel’s LiverChip platform. During the project, which commenced in December 2012 and involved the installation of a LiverChip device at a Sanofi research site, the company tested the human hepatocyte LiverChip system against current industry gold standard 2D plated cultures of primary hepatocytes.
 
Using LiverChip, Sanofi’s researchers were able to perform in depth DMPK analyses over much longer time courses of up to 6 days, including the accurate monitoring of dose clearance by the cytochrome P450 enzyme superfamily (CYPs), as well as the induction of CYP isoforms during drug metabolism. The study also confirmed that LiverChip does not suffer from any nonspecific drug binding, while the results exhibited good reproducibility, both within individual plates and between replicate experiments. 
 
As Emma Sceats, chief operating officer of Zyoxel, summarized: “Sanofi have been a very good partner and customer of Zyoxel, and are one of an increasing number of international pharmaceutical companies we are working with. The value proposition of LiverChip’s extended time window is proving especially useful for applications such as assessing low clearance compounds, formation and detection of rare metabolites and to study the impact of chronic multiple dosing. We believe that the system can become part of the routine process for preclinical drug testing, ensuring only high quality candidates are taken through to clinical trials. Ultimately, we hope this will facilitate the production of more effective medicines that exhibit fewer side effects, enhancing the future treatment of patients.”
 
 
Date: December 3, 2013
Source: Zyoxel
 
 
 
 

Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE